WALTHAM, Mass., June 05, 2023 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to...
ELI-002 was shown to be well-tolerated with no dose limiting toxicity or cytokine release syndromeA high proportion of patients had...
Early on-treatment ctDNA reduction in stable disease patients treated with KIMMTRAK was associated with longer overall survival (OXFORDSHIRE, England &...
New data emphasizes the value of MRD testing in predicting survival outcomes and informing the personalized treatment of patients with...
Dr. Wang appointed by the OBI Pharma Board of Directors as Chief Executive Officer to lead OBI Pharma with a...
SAN FRANCISCO, June 01, 2023 (GLOBE NEWSWIRE) -- Excision BioTherapeutics, Inc., a clinical-stage biotechnology company developing CRISPR-based therapies designed to...
DOYLESTOWN, Pa., May 30, 2023 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”), a biopharmaceutical company focused...
SAN DIEGO, May 30, 2023 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ: TCON), a clinical stage biopharmaceutical company focused on the...
New data show continued durability of response over 14 months with humoral immune responses increasing over time LAWRENCEVILLE, N.J., May...
HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., May 25, 2023 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM;...
Strong anti-tumor activity shown in a platinum-resistant ovarian cancer population, with a confirmed ORR of 50.0% and mPFS of 7.4...
- Nirogacestat Treatment Demonstrated Rapid, Sustained and Consistent Reductions in Pain Compared to Placebo Using Multiple Assessment Tools - -...
As of the data cutoff date, nine of the 14 evaluable patients treated with CUE-101+ KEYTRUDA® (pembrolizumab) demonstrated tumor regression,...
Highlighting application of the Molecular Biology Workstation to accelerating vaccine and biologics discoverySAN DIEGO, May 23, 2023 (GLOBE NEWSWIRE) --...
Latest patent broadens protection around OCEA’s platform of first-in-class anti-CHi3L1 therapeutic immunotherapy candidates, based on the breakthrough discovery by scientific...
SOUTH SAN FRANCISCO, Calif., May 23, 2023 (GLOBE NEWSWIRE) -- EPIC BIO, a biotechnology company developing therapies to modulate gene...
The best-in-class BrightInsight Platform accelerates the time to market for patient apps that enable biopharma companies to differentiate their therapies...
REDWOOD CITY, Calif., May 23, 2023 (GLOBE NEWSWIRE) -- Talis Biomedical Corporation (Nasdaq: TLIS), a diagnostic company dedicated to advancing...
GeneType featured on the Balancing Act Balance Act Set with Dr. Carolynn Young and Dr. Joel Evans GeneType Multi-risk Test...
Eascra Biotech Exploring Space Manufacturing Options on the International Space StationBOSTON, May 19, 2023 (GLOBE NEWSWIRE) -- Research from Eascra...